IL140225A0 - PHARMACEUTICAL COMPOSITIONS AND KITS CONTAINING ANDROST-5-EN-3beta; 17beta;-DIOL OR PRODRUGS THEREOF - Google Patents

PHARMACEUTICAL COMPOSITIONS AND KITS CONTAINING ANDROST-5-EN-3beta; 17beta;-DIOL OR PRODRUGS THEREOF

Info

Publication number
IL140225A0
IL140225A0 IL14022599A IL14022599A IL140225A0 IL 140225 A0 IL140225 A0 IL 140225A0 IL 14022599 A IL14022599 A IL 14022599A IL 14022599 A IL14022599 A IL 14022599A IL 140225 A0 IL140225 A0 IL 140225A0
Authority
IL
Israel
Prior art keywords
17beta
3beta
androst
prodrugs
diol
Prior art date
Application number
IL14022599A
Other languages
English (en)
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of IL140225A0 publication Critical patent/IL140225A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14022599A 1998-06-11 1999-06-10 PHARMACEUTICAL COMPOSITIONS AND KITS CONTAINING ANDROST-5-EN-3beta; 17beta;-DIOL OR PRODRUGS THEREOF IL140225A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9628698A 1998-06-11 1998-06-11
PCT/CA1999/000537 WO1999063973A2 (fr) 1998-06-11 1999-06-10 COMPOSITIONS PHARMACEUTIQUES ET UTILISATIONS POUR L'ANDROST-5-ENE-3β,17β-DIOL

Publications (1)

Publication Number Publication Date
IL140225A0 true IL140225A0 (en) 2002-02-10

Family

ID=22256669

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14022599A IL140225A0 (en) 1998-06-11 1999-06-10 PHARMACEUTICAL COMPOSITIONS AND KITS CONTAINING ANDROST-5-EN-3beta; 17beta;-DIOL OR PRODRUGS THEREOF
IL175723A IL175723A0 (en) 1998-06-11 2006-05-17 Pharmaceutical compositions and kits containing androst-5-ene-3??, 17??-diol or prodrugs thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL175723A IL175723A0 (en) 1998-06-11 2006-05-17 Pharmaceutical compositions and kits containing androst-5-ene-3??, 17??-diol or prodrugs thereof

Country Status (22)

Country Link
US (12) US6432940B1 (fr)
EP (2) EP1083904A2 (fr)
JP (1) JP2002517432A (fr)
KR (3) KR20060098399A (fr)
CN (3) CN1879630A (fr)
AR (1) AR018660A1 (fr)
AU (1) AU4127499A (fr)
BR (1) BR9911115A (fr)
CA (1) CA2334702C (fr)
HU (1) HUP0102483A3 (fr)
ID (1) ID27922A (fr)
IL (2) IL140225A0 (fr)
MX (1) MXPA00012304A (fr)
MY (1) MY131522A (fr)
NO (1) NO20006286L (fr)
NZ (1) NZ536787A (fr)
PL (1) PL345955A1 (fr)
RU (1) RU2221569C2 (fr)
TR (2) TR200102867T2 (fr)
TW (2) TWI263499B (fr)
WO (1) WO1999063973A2 (fr)
ZA (1) ZA200007299B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060098399A (ko) * 1998-06-11 2006-09-18 앙도르쉐르슈 인코포레이티드 안드로스트-5-엔-3β,17β-디올을 포함하는 약학 조성물 및그 용도
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20060079492A1 (en) * 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
KR20020011437A (ko) 1999-06-11 2002-02-08 추후보정 여성에 비-경구 안드로겐형 스테로이드의 투여
DE60043305D1 (de) 1999-07-06 2009-12-24 Endorech Inc Pharmazeutische zubereitungen zur behandlung von insulinresitenz
DE60045751D1 (de) * 1999-09-30 2011-04-28 Harbor Biosciences Inc Therapeutische Behandlung androgenrezeptorbedingter Leiden
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
FR2803750B1 (fr) * 2000-01-17 2004-04-02 Assist Publ Hopitaux De Paris Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs biologiques et de ses derives metaboliques comme anti-atrophiant
WO2001062259A1 (fr) * 2000-02-25 2001-08-30 Hollis Eden Pharmaceuticals Methode de traitement du cancer de la prostate
DE10039199A1 (de) * 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
FR2825277B1 (fr) * 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
DE10151363A1 (de) * 2001-10-17 2003-05-08 Schering Ag Somatotrope Therapie
WO2003070253A1 (fr) * 2002-02-21 2003-08-28 Pantarhei Bioscience B.V. Composant oestrogenique pour traiter la diminution de la libido chez les femmes
WO2003090754A1 (fr) * 2002-04-23 2003-11-06 Sahltech I Göteborg AB Utilisation de la dhea pour le traitement de l'hypopituitarisme chez la femme
JP2006506445A (ja) * 2002-08-28 2006-02-23 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 治療処置の方法
US20050101581A1 (en) * 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
CN1997374A (zh) * 2004-06-23 2007-07-11 默克公司 雌激素受体调节剂
CN102357248A (zh) 2004-10-20 2012-02-22 恩多研究公司 单独的性甾体前体或与选择性雌激素受体调节剂联合用于防治绝经后女性的阴道疾病和病症
MX2007005098A (es) * 2004-11-01 2008-01-16 Endorech Inc Uso de androgenos para reducir la probabilidad de adquirir o tratar el envejecimiento de la piel.
EP1967202A1 (fr) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Utilisation d'antagonistes LHTH pour le traitement des symptômes de tractus urinaires faibles, en particulier la vessie hyperactive et/ou hyperactivité du détrusor
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20090258850A1 (en) * 2007-08-21 2009-10-15 Frincke James M Stabilized therapeutic compositions and formulations
EP2053055A1 (fr) * 2007-10-24 2009-04-29 Bayer Schering Pharma Aktiengesellschaft 11.beta.-fluoro-3-acetoxyestra-3,5-dien-17-one et son procédé de fabrication
JP2010109894A (ja) * 2008-10-31 2010-05-13 Fujitsu Ltd 弾性波フィルタ、デュープレクサ、通信モジュール、および通信装置
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
KR20160088947A (ko) 2010-06-16 2016-07-26 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
US20130178747A1 (en) * 2012-01-10 2013-07-11 Peter J. Muran Breast cancer precursor evaluation system and proactive breast wellness program
CN105037532B (zh) * 2015-07-27 2018-02-09 苏州博源医疗科技有限公司 17‑酮类固醇免疫原、抗体和检测试剂及制备方法
CN111830169B (zh) * 2020-07-24 2022-07-12 中山大学 多囊卵巢综合征诊断的化合物及应用
US12578322B2 (en) 2020-12-07 2026-03-17 Kimberly-Clark Worldwide, Inc. Methods and consumer products for detecting a metabolite

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US424954A (en) * 1890-04-08 Table-knife
US279982A (en) * 1883-06-26 Thomas beid
US816689A (en) * 1904-07-07 1906-04-03 Charles M Stevenson Merry-go-round.
CH203260A (de) 1936-11-24 1939-02-28 Dreiding Boris Mittel zur örtlichen Erzeugung von Wärme.
US2185187A (en) * 1938-05-23 1940-01-02 Vlieg Gerard A De Rotary cutter
FR672M (fr) * 1960-08-31 1961-07-17
US3797444A (en) 1971-04-19 1974-03-19 H Stubbs Towing guide
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4139617A (en) * 1974-05-13 1979-02-13 Richardson-Merrell Inc. 19-Oxygenated-androst-5-enes for the enhancement of libido
US4040401A (en) 1974-11-05 1977-08-09 Ethyl Corporation Spark vacuum advance control
US4064654A (en) 1975-03-20 1977-12-27 H. G. Olson & Co., Inc. Sealed closures with weather stripping
JPS53144014A (en) 1977-05-20 1978-12-15 Masaya Koyama Automatic sprayer
DE3333240A1 (de) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4634694A (en) 1984-01-14 1987-01-06 Akzo N.V. Novel Δ4 - and Δ5 -androstene derivatives and pharmaceutical compositions containing these derivatives
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US5155045A (en) * 1985-01-25 1992-10-13 Trustees Of The University Of Penn. Use of male essence to alter female endocrine response
US4666441A (en) 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US5887216A (en) * 1997-03-19 1999-03-23 Ricoh Company, Ltd. Method and system to diagnos a business office device based on operating parameters set by a user
US5686465A (en) * 1988-10-31 1997-11-11 Endorecherche Inc. Sex steroid activity inhibitors
KR900701242A (ko) 1988-12-01 1990-12-01 스타이너 브이. 캔스타드 에스트라디올의 경피전달용 조성물
US5461042A (en) * 1988-12-30 1995-10-24 Loria; Roger M. Regulation of the immune system
AU5856090A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5641768A (en) * 1989-11-17 1997-06-24 Loria; Roger M. 5-androstene 3β, 17β diol for treatment
US5071644A (en) 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US5506223A (en) * 1990-08-29 1996-04-09 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
US5206008A (en) * 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
JPH07504198A (ja) * 1992-02-24 1995-05-11 イースト カロライナ ユニバーシティ デヒドロエピアンドロステロンおよびその類縁体を用いる処置によって発癌を抑制する方法
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
EP0680327B1 (fr) 1993-01-19 2004-09-15 Endorecherche Inc. Procedes therapeutiques et systemes d'apport de deshydroepiandrosterone
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5387583A (en) * 1993-04-20 1995-02-07 Loria; Roger M. Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof
US5571933A (en) * 1994-11-17 1996-11-05 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
ES2098193B1 (es) * 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
US5828688A (en) * 1995-10-26 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Method and apparatus for linewidth reduction in distributed feedback or distributed bragg reflector semiconductor lasers using vertical emission
US6653331B2 (en) * 1996-07-03 2003-11-25 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
IT1292129B1 (it) * 1997-06-11 1999-01-25 Sunnimex Ltd Medicamento utile per ridurre la massa grassa ed aumentare la massa magra nella donna in menopausa ed in entrambi i sessi nella
WO1999007381A1 (fr) * 1997-08-11 1999-02-18 Weider Nutrition International, Inc. Compositions et traitements permettant de reduire les effets secondaires lies a l'administration des precurseurs de la testosterone androgenique
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
AU740758B2 (en) * 1997-10-28 2001-11-15 Vivus, Inc. Treatment of female sexual dysfunction
KR20060098399A (ko) * 1998-06-11 2006-09-18 앙도르쉐르슈 인코포레이티드 안드로스트-5-엔-3β,17β-디올을 포함하는 약학 조성물 및그 용도
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6284262B1 (en) * 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
DE60043305D1 (de) * 1999-07-06 2009-12-24 Endorech Inc Pharmazeutische zubereitungen zur behandlung von insulinresitenz
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
CA2446849A1 (fr) * 2001-05-16 2002-11-21 Endeavor Pharmaceuticals Traitement d'etats lies a un deficit en hormones par administration de progestatifs

Also Published As

Publication number Publication date
US20020187967A1 (en) 2002-12-12
US20020187965A1 (en) 2002-12-12
US20020187963A1 (en) 2002-12-12
NZ536787A (en) 2006-03-31
ID27922A (id) 2001-05-03
US6884795B2 (en) 2005-04-26
US20020187970A1 (en) 2002-12-12
NO20006286L (no) 2001-01-31
US6964955B2 (en) 2005-11-15
PL345955A1 (en) 2002-01-14
HK1078004A1 (en) 2006-03-03
TR200100063T2 (tr) 2001-05-21
IL175723A0 (en) 2006-09-05
WO1999063973A3 (fr) 2000-11-02
WO1999063973A2 (fr) 1999-12-16
CA2334702A1 (fr) 1999-12-16
HK1037329A1 (en) 2002-02-08
US20020187969A1 (en) 2002-12-12
US20020187964A1 (en) 2002-12-12
EP1731157A2 (fr) 2006-12-13
HUP0102483A3 (en) 2002-11-28
CN1243550C (zh) 2006-03-01
KR100679735B1 (ko) 2007-02-07
US6995150B2 (en) 2006-02-07
AR018660A1 (es) 2001-11-28
MXPA00012304A (es) 2003-05-15
KR20010052764A (ko) 2001-06-25
CN100377711C (zh) 2008-04-02
TWI283579B (en) 2007-07-11
CN1626095A (zh) 2005-06-15
AU4127499A (en) 1999-12-30
TR200102867T2 (fr) 2002-06-21
JP2002517432A (ja) 2002-06-18
US20020187962A1 (en) 2002-12-12
US20080161277A1 (en) 2008-07-03
EP1731157A3 (fr) 2009-07-15
CN1311682A (zh) 2001-09-05
US20020187968A1 (en) 2002-12-12
TWI263499B (en) 2006-10-11
ZA200007299B (en) 2002-04-24
US6432940B1 (en) 2002-08-13
RU2221569C2 (ru) 2004-01-20
KR20060098399A (ko) 2006-09-18
CN1879630A (zh) 2006-12-20
TW200630101A (en) 2006-09-01
US20020187966A1 (en) 2002-12-12
HUP0102483A2 (hu) 2001-11-28
EP1083904A2 (fr) 2001-03-21
MY131522A (en) 2007-08-30
NO20006286D0 (no) 2000-12-11
CA2334702C (fr) 2005-10-18
BR9911115A (pt) 2001-12-04
US20020187973A1 (en) 2002-12-12
KR20060098400A (ko) 2006-09-18

Similar Documents

Publication Publication Date Title
IL175723A0 (en) Pharmaceutical compositions and kits containing androst-5-ene-3??, 17??-diol or prodrugs thereof
HUP0103256A3 (en) Thiobenzimidazole derivatives and pharmaceutical compositions containing the compounds
IL138899A0 (en) Amidene derivatives and pharmaceutical compositions containing the same
HU9901606D0 (en) Pharmaceutical compositions
IL143920A0 (en) 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same
GB9827996D0 (en) Pharmaceutical Compositions
PL343627A1 (en) Medicinal compositions
PT1466615E (pt) Composição farmacêutica
PL343769A1 (en) Pharmaceutical composition
AU5565099A (en) Pharmaceutical compositions and methods for use
GB2341692B (en) Resist composition
GB9818591D0 (en) Pharmaceutical composition
GB9809213D0 (en) Pharmaceutical compositions
EG24463A (en) Modified release pharmaceutical composition
HUP0101733A3 (en) Pharmaceutical compositions containing sulfonyl-dipeptides and their use
HUP0104852A3 (en) Oktahydro-pyrido-pyrazine derivatives and pharmaceutical compositions containing the same and their use
GB9803521D0 (en) New compounds and pharmaceutical compositions thereof
AU7432698A (en) Disinfectant composition
GB9802472D0 (en) Pharmaceutical compositions
AU2880699A (en) Pharmaceutical compositions and methods for use
GB9618376D0 (en) Pharmaceutical compositions
GB9806487D0 (en) Pharmaceutical compositions
HU9800078D0 (en) Pharmaceutical composition
HUP0002775A3 (en) Alkyl-4-silyl-furane or tiophene substituted phenols and thiophenols and pharmaceutical compositions thereof
AU7826198A (en) Pharmaceutical compositions containing alpha-tocopherylphosphocholine